Previous 10 | Next 10 |
Gainers: SEDG +18.5% . AVID +10.2% . APT +9.3% . AIG +6.4% . LCI +5.7% . More news on: SolarEdge Technologies, Inc., Avid Technology, Inc., Alpha Pro Tech, Ltd., Stocks on the move, Read more ...
Intersect ENT, Inc. (NASDAQ: XENT ): Q1 GAAP EPS of -$0.35 misses by $0.05 . More news on: Intersect ENT, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019. Total revenue was $26.7 million for the first quarter of 2019 compare...
Lisa Earnhardt to Step Down as CEO, Will Remain on Board of Directors Kieran Gallahue Appointed Interim CEO and Executive Chairman of the Board Intersect ENT ® , Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions...
Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas, including a Q&A session at 1:40 p.m. PT. A replay of the session will be ava...
Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019. The company expects to issue the release at approximately 4:00 p.m. ET and mana...
Intersect ENT (XENT) Q4 2018 Earnings Conference Call February 25, 2019, 04:30 PM ET Company Participants Lisa Earnhardt - President & CEO Jeryl Hilleman - CFO Conference Call Participants Bob Hopkins - Bank of America Richard Newitter - SVB Leerink Matthew O'Brien - ...
Intersect ENT (NASDAQ: XENT ): Q4 GAAP EPS of -$0.16 misses by $0.01 . More news on: Intersect ENT, Earnings news and commentary, Healthcare stocks news, Read more ...
ENCORE Clinical Study Completed, Primary Endpoints Met Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and full year ended December 31, 20...
ALSN , APLE , APTS , ATH , AWR , BWXT , CDEV , CORT , CRZO , DRH , ELGX , EPR , ETSY , FRAC , FRGI , GSM , HNI , HTZ , IMMU , JBT , KAMN , KBR , LSI , MEDP , MOS , NGHC , NLS , OFIX , OKE , PBPB , PEB , PLOW , PODD , QTS , RCII , RP , RRC , SHAK , SNHY...
News, Short Squeeze, Breakout and More Instantly...
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including a...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third qu...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to...